Johns Hopkins University President Ronald J. Daniels is scrambling to track down funding for young researchers who are increasingly being passed up for federal grants.
Facebook generates about $8 a year in revenue from each of its users. But what if you offered a company not just your photos and updates, but your entire genome?
Then you could be worth as much as $20,000.
Hundreds of research papers are published every day worldwide. But which articles are most discussed and in which circles? To find out, Altmetric in London traced how often papers were noted in 14 digital channels, ranging from the serious (5,000 research blogs and Mendeley, an academic citation network) to the trendy (Twitter, Facebook) and everything in between (including 1,000 news outlets). Altmetric poured data for 2014 into an algorithm that created scores; the top 200 articles are mapped here.
R. Mike Gill, chairman of Columbia investment banking firm Evergreen Advisors, will become the next secretary of the Maryland Department of Business and Economic Development.
The appointment ends months of speculation about who Gov.-elect Larry Hogan, a Republican, would name to the role after winning the gubernatorial election in November.
A new $75 million investment fund has been created by Connecticut-based HealthInvest Equity Partners, according to a filing with the SEC.
The investment firm, formed in 2013, focuses on a wide range of areas within healthcare, from woman’s health companies to urgent care providers to medical imaging.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.
The EAGB put together a year-end report on the regional economy for the second year, this time highlighting local universities and the innovation economy. Also in this report, the EAGB lists its most memorable achievements from the previous year. Take a look!
According to a recent article in The National Law Review, universities controlling and supporting the commercialization of their own research is not a new trend in the academic world. Recently, for example, the University of California created UC Ventures, “an independent fund to pursue investments in UC research-fueled enterprises” in September 2014, stated the school in a press release.
Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today that it has raised $25 million in Series A funding. Vtesse is the first spin-off company for Cydan Development, Inc., an orphan-drug accelerator that shares with Vtesse the same syndicate of leading life sciences investors that are committed to funding additional rare disease companies. New Enterprise Associates (NEA) led the Vtesse financing with participation from Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.
The University of Maryland will be applying for status as a qualified institution to give tax breaks to businesses — particularly startups — located around some of College Park’s higher-profile locales, such as the planned hotel-conference center and research park.